Document 0295
 DOCN  M9440295
 TI    Solid-phase extraction combined with radioimmunoassay for measurement of
       zalcitabine (2',3'-dideoxycytidine) in plasma and serum.
 DT    9404
 AU    Roberts WL; Buckley TJ; Rainey PM; Jatlow PI; Department of Laboratory
       Medicine, Yale University School of; Medicine, New Haven, CT 06510.
 SO    Clin Chem. 1994 Feb;40(2):211-5. Unique Identifier : AIDSLINE
       MED/94147642
 AB    Of the antiviral agents that are currently in clinical use in the US for
       therapy for human immunodeficiency virus infections, zalcitabine (ddC)
       is the most potent and is effective at the lowest plasma concentrations.
       The two reported procedures for measuring these low concentrations
       involve a chromatographic technique coupled with mass spectrometry. We
       have developed a procedure combining solid-phase extraction with a
       strong cation-exchange resin and commercially available RIA reagents for
       the quantification of ddC in plasma or serum. The method demonstrates
       good linearity, specificity, and precision, with overall CVs of < 10%
       from 2-20 micrograms/L and 17% at 0.8 microgram/L (the lower limit of
       quantitation). No significant cross-reactivity with nucleoside analogs
       other than ddC analogs was noted. The major advantages of this assay are
       its efficiency and relative simplicity, which should facilitate its
       performance in many laboratories.
 DE    Antiviral Agents/*BLOOD  Biological Availability  Half-Life  Human  Male
       Quality Control  *Radioimmunoassay/STATISTICS & NUMER DATA  Sensitivity
       and Specificity  Support, Non-U.S. Gov't  Support, U.S. Gov't, P.H.S.
       Zalcitabine/*BLOOD/PHARMACOKINETICS  Zidovudine/BLOOD  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).